Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
The move signals a major expansion milestone for the Swiss laboratory automation company
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
Sarin will focus on advancing scalable AI-driven platforms and strengthening the company’s global data science capabilities across healthcare and enterprise technology domains
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Transition to a fermentation-based globally integrated CDMO platform
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
